402 related articles for article (PubMed ID: 33918941)
1. Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
Kim KS; Kim DH; Kim DH
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918941
[TBL] [Abstract][Full Text] [Related]
2. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy.
Murugan D; Murugesan V; Panchapakesan B; Rangasamy L
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358857
[TBL] [Abstract][Full Text] [Related]
4. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
Kumar V; Mahato RI
Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
[TBL] [Abstract][Full Text] [Related]
6. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
7. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
8. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
Gras Navarro A; Björklund AT; Chekenya M
Front Immunol; 2015; 6():202. PubMed ID: 25972872
[TBL] [Abstract][Full Text] [Related]
10. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
12. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
Phung CD; Tran TH; Kim JO
Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
[TBL] [Abstract][Full Text] [Related]
13. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
14. Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.
Seliger B; Koehl U
Front Immunol; 2022; 13():910595. PubMed ID: 36045670
[TBL] [Abstract][Full Text] [Related]
15. Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.
Biber G; Sabag B; Raiff A; Ben-Shmuel A; Puthenveetil A; Benichou JIC; Jubany T; Levy M; Killner S; Barda-Saad M
EMBO Mol Med; 2022 Jan; 14(1):e14073. PubMed ID: 34725941
[TBL] [Abstract][Full Text] [Related]
16. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
17. Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.
Mendoza-Valderrey A; Alvarez M; De Maria A; Margolin K; Melero I; Ascierto ML
Cells; 2022 Oct; 11(19):. PubMed ID: 36231109
[TBL] [Abstract][Full Text] [Related]
18. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment.
Navin I; Lam MT; Parihar R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371456
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
20. Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity.
Mikelez-Alonso I; Magadán S; González-Fernández Á; Borrego F
Adv Drug Deliv Rev; 2021 Sep; 176():113860. PubMed ID: 34237404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
